Repligen Corporation

    Jurisdiction
    United States
    LEI
    54930006QJ0T5AUO1E71
    ISIN
    US7599161095 (RGEN)
    Sectors
    1. Healthcare
    2. Medical - Instruments & Supplies

    Scores

    InsiderPie Expert Score
    49 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Read full profile

    Fundamentals

    Net revenue
    €574.85M
    Gross margin
    17.3%
    EBIT
    -€20.35M
    EBIT margin
    -3.5%
    Net income
    -€11.79M
    Net margin
    -2.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €704.54M +22.6% €107.71M -1,013.3%
    €812.03M +15.3% €141.78M +31.6%
    €923.21M +13.7% €190.71M +34.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Madaus Martin D N/A +1.8K $112.13 +$201.83K

    Congress transactions

    Name Transaction date Value
    Lisa McClain August 13, 2025 $1.00K–$15.00K
    Lisa McClain August 13, 2025 $1.00K–$15.00K
    Jefferson Shreve May 8, 2025 $15.00K–$50.00K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Nancy Zevenbergen 86K $10.70M -1.6K Sell

    Earnings Calls

    Latest earnings call: May 1, 2024 (Q1 2024)

    Add to watchlist

    Notifications